Novartis AG (NYSE: NVS) stock has achieved $93.25 in the past week


Novartis AG (NYSE:NVS) saw a downside of -0.21% to close Tuesday at $92.02 after subtracting -$0.19 on the day. The 5-day average trading volume is 2,000,160 shares of the company’s common stock. It has gained $93.25 in the past week and touched a new high 1 time within the past 5 days. An average of 2,016,540 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,956,784.

NVS’s 1-month performance is 1.23% or $1.15 on its low of $87.00 reached on 01/24/23. The company’s shares have touched a 52-week low of $74.09 and high of $94.26, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, NVS has achieved 1.43% or $1.30 and has reached a new high 5 times. However, the current price is down -2.38% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

NVS stock has a beta of 0.54. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.24 while the price-to-book (PB) in the most recent quarter is 3.28, with the price to cash flow ratio at 42.27.

Novartis AG’s quick ratio for the period ended September 29 was 1.10, with the current ratio over the same period at 1.30. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.35, while the total debt to equity was 0.47.. In terms of profitability, the gross margin trailing 12 months is 71.00%. The trailing 12-month EBITDA margin is 33.62% while for the period ending September 29, Novartis AG’s operating margin was 18.80%. The firm’s gross profit as reported stood at $37.01 billion against revenue of $52.88 billion.

Earnings Surprise

For the quarterly period ending September 29 this year, Novartis AG’s cash and short-term investments amounted to $278.0 million against total debt of $28.54 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 66.4% to $24.02 billion, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected NVS to announce $1.55 per share in earnings in its latest quarter, but it posted $1.58, representing a 1.90% surprise. EBITDA for the quarter stood at more than $2.17 billion. NVS stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 57.57 billion, with total debt at $28.54 billion.

Let’s look briefly at Novartis AG (NVS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 56.92% to suggest the stock is trending Neutral, with historical volatility in this time period at 7.71%.

The stock’s 5-day moving average is $92.14, reflecting a -0.39% or -$0.36 change from its current price. NVS is currently trading +1.23% above its 20-day SMA, +13.94% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +10.91% and SMA200 by+1.51%.

Stochastic %K and %D was 72.77% and 70.66% and the average true range (ATR) pointed at 1.59. The RSI (14) points at 57.78%, while the 14-day stochastic is at 80.32% with the period’s ATR at 1.46. The stock’s 9-day MACD Oscillator is pointing at 0.42 and 0.64 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Novartis AG (NYSE: NVS), Stifel upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for NVS stock have a consensus rating for the stock as Hold. Currently, 4 brokerage advisors rate NVS as a “sell,”, while 13 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 7 have offered a “buy” rating.

What is NVS’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $76.02 and a high of $114.03, with their median price target at $94.47. Looking at these predictions, the average price target given by analysts is for Novartis AG (NVS) stock is $95.60.


Please enter your comment!
Please enter your name here